Novo Nordisk Launches Wegovy® in Malaysia to Tackle Obesity and Cardiovascular Risks
Novo Nordisk has officially announced the availability of Wegovy® (semaglutide 2.4 mg) in Malaysia, marking a significant milestone in the country’s fight against obesity and its related health complications. The….